Altimmune Inc (ALT)

$7.03 +0.25 (3.69%)
Market Cap 549.91M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.00
Volume 7,853,600
Avg Vol 2,836,392
Day's Range N/A - N/A
Shares Out 81.11M
Stochastic %K 75%
Beta 0.58
Analysts Strong Sell
Price Target $22.38

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
Oziboz
Oziboz Jun. 21 at 8:24 AM
$ALT i had a dream last nite it hit 20 and halted there for hours i sold 1k then it went up to 142$ i was a millonier
0 · Reply
Space_Dust
Space_Dust Jun. 21 at 8:09 AM
$ALT Nobody on this board knows what is happening...we are paws in this game...some of us like me think we are smart pawns, because we survived..if you know what is going to happen it's because you are corrupt...most casinos, even run by the mob, are more ethical than Wallstreet
1 · Reply
TaxEagle1040
TaxEagle1040 Jun. 21 at 8:05 AM
$ALT If we are even luckier, PFE and GILD will get into a bidding war over ALT. The higher the price, the better! Remember, I have labeled ALT, the millionaire maker stock!
0 · Reply
Dennis123x
Dennis123x Jun. 21 at 7:34 AM
$ALT I'm beginning more and more to believe Gilead Sciences will acquire Altimmune. It makes sense based on where they are at and their future intentions with MASH.
0 · Reply
TaxEagle1040
TaxEagle1040 Jun. 21 at 7:13 AM
$ALT PFE is closing in! If we are lucky, they are in merger talks that result in $50-$100 per share acquisition!!
0 · Reply
Space_Dust
Space_Dust Jun. 21 at 7:08 AM
$ALT Boys and Girls...pemvidutide is awesome, but if they don't announce the clinical trial results on Monday or Tuesday...there is big money screwing retail...I have been wounded being too optimistic and doing options..playing with $100K..rolled it forward but only $60K now..betting on Dr Garg will do it before June 27th...you can be right and wrong with the stock market..it really is a corrupt system...
2 · Reply
GreenEnergy2022
GreenEnergy2022 Jun. 21 at 6:52 AM
$ALT Bourla said during ER, 2-3 deals up to 15B. Correct me if Im wrong, but the goal was within this year? He will need to start soon.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Jun. 21 at 6:51 AM
$ALT My take on Vktx is that I would not even touch the stock. For me to invest there they will need to stand out out, and not only have weight loss % numbers. If they dont do something soon to stand out, it will be a race to the bottom. I am 100% sure ALT will overtake Vktx in mcap this year.
0 · Reply
steeltech
steeltech Jun. 21 at 6:06 AM
$ALT guys, bio rich went to the proctologist, but from what I understand they don't have much Vaseline. What do you say? Should we raise money to buy him Vaseline?
0 · Reply
APLD
APLD Jun. 21 at 5:46 AM
$ALT i think its too risky to try timing a small biotech like altimmune, especially if data is stellar as expected… not worth the speculation
2 · Reply
Latest News on ALT
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

Jun 13, 2025, 7:30 AM EDT - 7 days ago

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

Jun 2, 2025, 10:51 AM EDT - 18 days ago

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

VKTX

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

May 29, 2025, 10:25 AM EDT - 22 days ago

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

May 19, 2025, 7:30 AM EDT - 4 weeks ago

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune to Participate at Two Upcoming Investor Conferences

May 14, 2025, 7:30 AM EDT - 5 weeks ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:57 PM EDT - 5 weeks ago

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

Altimmune Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025, 7:00 AM EDT - 5 weeks ago

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

May 13, 2025, 7:00 AM EDT - 5 weeks ago

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

HTGC

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

May 8, 2025, 7:30 AM EDT - 6 weeks ago

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 6, 2025, 7:30 AM EDT - 6 weeks ago

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

May 1, 2025, 7:30 AM EDT - 7 weeks ago

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

Altimmune to Participate in the Citizens Life Sciences Conference

Apr 30, 2025, 7:30 AM EDT - 7 weeks ago

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Mar 17, 2025, 3:21 PM EDT - 3 months ago

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Mar 13, 2025, 5:26 PM EDT - 3 months ago

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Altimmune to Host Virtual R&D Day on March 13, 2025

Mar 6, 2025, 7:30 AM EST - 3 months ago

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Participate in the Leerink Global Healthcare Conference

Mar 3, 2025, 7:30 AM EST - 3 months ago

Altimmune to Participate in the Leerink Global Healthcare Conference

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Feb 28, 2025, 2:15 PM EST - 4 months ago

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:24 PM EST - 4 months ago

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 27, 2025, 7:00 AM EST - 4 months ago

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Feb 25, 2025, 7:30 AM EST - 4 months ago

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 20, 2025, 7:30 AM EST - 4 months ago

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Feb 18, 2025, 5:26 AM EST - 4 months ago

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Final Trade: WST, BTC, GLD, ALT

Feb 14, 2025, 6:32 PM EST - 4 months ago

Final Trade: WST, BTC, GLD, ALT

GLD BTC WST

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 5 months ago

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Altimmune Could Find A Partner For Its Phase 3 Exercise

Dec 30, 2024, 11:42 AM EST - 6 months ago

Altimmune Could Find A Partner For Its Phase 3 Exercise

Altimmune Added to Nasdaq Biotechnology Index

Dec 19, 2024, 7:30 AM EST - 6 months ago

Altimmune Added to Nasdaq Biotechnology Index

Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 16, 2024, 3:14 AM EST - 6 months ago

Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune CEO on what's next for its experimental obesity drug

Dec 3, 2024, 6:04 PM EST - 7 months ago

Altimmune CEO on what's next for its experimental obesity drug

Final Trade: C, NVDA, XLF, ALT

Nov 19, 2024, 6:29 PM EST - 7 months ago

Final Trade: C, NVDA, XLF, ALT

NVDA XLF C

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Nov 15, 2024, 11:00 AM EST - 7 months ago

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge

Nov 13, 2024, 3:43 PM EST - 7 months ago

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 13, 2024, 12:38 PM EST - 7 months ago

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:00 AM EST - 7 months ago

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 11, 2024, 7:30 AM EST - 7 months ago

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Nov 11, 2024, 7:30 AM EST - 7 months ago

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Nov 7, 2024, 7:30 AM EST - 8 months ago

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Nov 4, 2024, 7:30 AM EST - 8 months ago

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

Oct 15, 2024, 8:00 AM EDT - 8 months ago

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

Consider Buying Potential Takeover Target Altimmune

Oct 2, 2024, 2:48 PM EDT - 9 months ago

Consider Buying Potential Takeover Target Altimmune

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Oct 1, 2024, 7:30 AM EDT - 9 months ago

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sep 30, 2024, 7:30 AM EDT - 9 months ago

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21, 2024, 5:21 AM EDT - 9 months ago

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Sep 10, 2024, 1:09 PM EDT - 10 months ago

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Sep 10, 2024, 7:45 AM EDT - 10 months ago

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Sep 3, 2024, 7:30 AM EDT - 10 months ago

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27, 2024, 11:26 AM EDT - 10 months ago

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 9:03 AM EDT - 11 months ago

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Aug 1, 2024, 7:30 AM EDT - 11 months ago

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Oziboz
Oziboz Jun. 21 at 8:24 AM
$ALT i had a dream last nite it hit 20 and halted there for hours i sold 1k then it went up to 142$ i was a millonier
0 · Reply
Space_Dust
Space_Dust Jun. 21 at 8:09 AM
$ALT Nobody on this board knows what is happening...we are paws in this game...some of us like me think we are smart pawns, because we survived..if you know what is going to happen it's because you are corrupt...most casinos, even run by the mob, are more ethical than Wallstreet
1 · Reply
TaxEagle1040
TaxEagle1040 Jun. 21 at 8:05 AM
$ALT If we are even luckier, PFE and GILD will get into a bidding war over ALT. The higher the price, the better! Remember, I have labeled ALT, the millionaire maker stock!
0 · Reply
Dennis123x
Dennis123x Jun. 21 at 7:34 AM
$ALT I'm beginning more and more to believe Gilead Sciences will acquire Altimmune. It makes sense based on where they are at and their future intentions with MASH.
0 · Reply
TaxEagle1040
TaxEagle1040 Jun. 21 at 7:13 AM
$ALT PFE is closing in! If we are lucky, they are in merger talks that result in $50-$100 per share acquisition!!
0 · Reply
Space_Dust
Space_Dust Jun. 21 at 7:08 AM
$ALT Boys and Girls...pemvidutide is awesome, but if they don't announce the clinical trial results on Monday or Tuesday...there is big money screwing retail...I have been wounded being too optimistic and doing options..playing with $100K..rolled it forward but only $60K now..betting on Dr Garg will do it before June 27th...you can be right and wrong with the stock market..it really is a corrupt system...
2 · Reply
GreenEnergy2022
GreenEnergy2022 Jun. 21 at 6:52 AM
$ALT Bourla said during ER, 2-3 deals up to 15B. Correct me if Im wrong, but the goal was within this year? He will need to start soon.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Jun. 21 at 6:51 AM
$ALT My take on Vktx is that I would not even touch the stock. For me to invest there they will need to stand out out, and not only have weight loss % numbers. If they dont do something soon to stand out, it will be a race to the bottom. I am 100% sure ALT will overtake Vktx in mcap this year.
0 · Reply
steeltech
steeltech Jun. 21 at 6:06 AM
$ALT guys, bio rich went to the proctologist, but from what I understand they don't have much Vaseline. What do you say? Should we raise money to buy him Vaseline?
0 · Reply
APLD
APLD Jun. 21 at 5:46 AM
$ALT i think its too risky to try timing a small biotech like altimmune, especially if data is stellar as expected… not worth the speculation
2 · Reply
Calvary316
Calvary316 Jun. 21 at 5:41 AM
$ALT
0 · Reply
Willburn1
Willburn1 Jun. 21 at 5:05 AM
$ALT I have trust
0 · Reply
brambo13
brambo13 Jun. 21 at 4:59 AM
$ALT honey wake the kids up, it’s Friday night and $ALT trending !
0 · Reply
Niconiconee
Niconiconee Jun. 21 at 4:33 AM
$ALT midnight trending?
1 · Reply
jasonsdawg
jasonsdawg Jun. 21 at 4:29 AM
$ALT has apparently gotten rid of Homer. He is now using FUD and dumb posts elsewhere. But, I like to keep lists. Say when, Homa. Say when. $ALT
0 · Reply
Al_alex
Al_alex Jun. 21 at 4:15 AM
$ALT
0 · Reply
romanaround
romanaround Jun. 21 at 4:06 AM
$ALT $MDGL $VKTX
0 · Reply
ERAU15
ERAU15 Jun. 21 at 3:53 AM
$ALT trending number 1 cause….
1 · Reply
D0C_H0LLIDAY
D0C_H0LLIDAY Jun. 21 at 3:47 AM
$ALT 6/20/25 38,193 watchers
0 · Reply
Moonfish1
Moonfish1 Jun. 21 at 3:47 AM
$ALT let's fking gooooooooo
0 · Reply
bigmacsmallfries
bigmacsmallfries Jun. 21 at 3:46 AM
$ALT hope this our big week coming up. Would be really surprised if news was released June 30th. Crossing my fingers for this Monday or Tuesday.
0 · Reply
jmmoore4
jmmoore4 Jun. 21 at 3:45 AM
$ALT Oh, #1 you say?! 🤩
0 · Reply